An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic SyndromesInterventions: Drug: Group 2: Placebo; Drug: Group 1: Epoetin alfaSponsor: Janssen-Cilag International NVActive, not recruiting - verified June 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2011 Category: Research Source Type: clinical trials
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic SyndromesInterventions: Drug: Group 2: Placebo; Drug: Group 1: Epoetin alfaSponsor: Janssen-Cilag International NVActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2011 Category: Research Source Type: clinical trials
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic SyndromesInterventions: Drug: Group 2: Placebo; Drug: Group 1: Epoetin alfaSponsor: Janssen-Cilag International NVActive, not recruiting - verified February 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2011 Category: Research Source Type: clinical trials
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
Conditions: Anemia; Chronic Kidney DiseaseInterventions: Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline; Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline; Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at BaselineSponsor: Merck Sharp & Dohme Corp.Terminated - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Biological: Epoetin Alfa; Other: Laboratory Biomarker Analysis; Drug: LenalidomideSponsor: National Cancer Institute (NCI)Recruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Drug: Lenalidomide; Biological: Epoetin Alfa; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic SyndromesInterventions: Drug: lenalidomide; Biological: epoetin alfa; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Recruiting - verified June 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Drug: Lenalidomide; Biological: Epoetin Alfa; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic SyndromesInterventions: Drug: lenalidomide; Biological: epoetin alfa; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Recruiting - verified June 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Drug: Lenalidomide; Biological: Epoetin Alfa; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic SyndromesInterventions: Drug: lenalidomide; Biological: epoetin alfa; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Recruiting - verified June 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
